Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,357,567

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,357,567 protect, and when does it expire?

Patent 10,357,567 protects LEVULAN and is included in one NDA.

This patent has six patent family members in three countries.

Summary for Patent: 10,357,567
Title:Methods for photodynamic therapy
Abstract: A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.
Inventor(s): Lundahl; Scott (Lexington, MA), Guttadauro; Michael (Carlisle, MA)
Assignee: DUSA Pharmaceuticals, Inc. (Wilmington, MA)
Application Number:15/869,164
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,357,567
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 10,357,567

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Dusa LEVULAN aminolevulinic acid hydrochloride SOLUTION;TOPICAL 020965-001 Dec 3, 1999 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF ACTINIC KERATOSES OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,357,567

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2019200152 ⤷  Try it Free
Australia 2020103365 ⤷  Try it Free
Australia 2020267186 ⤷  Try it Free
Australia 2021102111 ⤷  Try it Free
Canada 3029792 ⤷  Try it Free
Japan 2019123708 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.